Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome (Kymes)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01168700|
Recruitment Status : Unknown
Verified July 2010 by Universidad de Santander.
Recruitment status was: Recruiting
First Posted : July 23, 2010
Last Update Posted : July 23, 2010
Many studies have addressed the relationship between metabolic syndrome and cardiovascular disease. Risk factors include abdominal obesity, insulin resistance, abnormal lipid profile and hypertension. It is proposed that this condition leads to an increase in the production of inflammatory substances and endothelial dysfunction.
New therapies have been studied to improve control of metabolic disorders and reduce the endothelium damage. Aged garlic extract (Kyolic®) is a promising intervention that has antithrombotic and antioxidant properties. At the moment there is not data about the effects of supplementation with AGE in the endothelial function of patients with metabolic syndrome. Thus, the purpose of this study is to investigate if the supplementation with Kyolic® can alter the plasma levels of inflammatory markers, insulin and the endothelial function of patients with metabolic syndrome.
Methods and design: A randomized, cross over, double-blind, placebo-controlled trial will be performed to assess the effects of 1.2 g of Kyolic in insulin resistance and endothelial function of 46 patients with diagnosis of metabolic syndrome. The participants will be recruited from the primary care centers from E.S.E ISABU Bucaramanga. All subjects who meet the inclusion criteria will be randomly assigned to two periods of 12 weeks (Kyolic and placebo). Control visits will be programmed monthly to verify compliance and the presence of adverse events. Outcome variables (endothelial function assessed by flow mediated vasodilation, inflammatory markers, insulin plasma levels) will be evaluated at the initial visit and after 12 and 24 weeks of treatment.
|Condition or disease||Intervention/treatment||Phase|
|Metabolic Syndrome||Drug: aged garlic extract Drug: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||46 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES"|
|Study Start Date :||November 2009|
|Estimated Primary Completion Date :||August 2010|
|Estimated Study Completion Date :||October 2010|
Placebo Comparator: Placebo
Placebo 1.2 g per day for 12 weeks, followed by a second treatment period with aged garlic extract during 12 more weeks.
Placebo 1.2 g per day for 12 weeks.
Experimental: Aged garlic extract (Kyolic ®)
Aged garlic extract, 1.2 g per day for 12 weeks, followed by a second treatment period with placebo during 12 more weeks.
Drug: aged garlic extract
Aged garlic extract, 1.2 g per day for 12 weeks
Other Name: Kyolic
- Endothelial function assessed by flow mediated vasodilation and plasma levels of nitrites/nitrates [ Time Frame: 12, 24 weeks ]
The flow mediated vasodilation is a non-invasive diagnostic test using high-resolution doppler ultrasound, that measures the changes in diameter of the brachial artery in response to increased blood flow (reactive hyperemia).
The plasma levels of nitrites/nitrates will be determined by immunoassay (R&D Systems, Inc)
- Plasma concentrations of C-reactive protein and interleukin-6 [ Time Frame: 12, 24 weeks ]During the initial and follow-up visits, a blood sample will be taken to determine C-reactive protein by high sensitivity chemiluminescent immunometric assay (IMMULITE 1000, DPC, Los Angeles, CA) and Interleukin-6 by immunoassay (Biosource International, Camarillo, CA)
- Plasma insulin and glucose levels [ Time Frame: 12, 24 weeks ]Blood samples will be taken at the initial and follow-up visits (12,24 weeks) to determine blood glucose by automatic colorimetric method (Baker System 9120 AX, Biochem Immunosystem, Allentown, PA)and insulin plasma levels by high sensitivity chemiluminescent immunometric assay (IMMULITE 1000, DPC, Los Angeles, CA).
- Waist and hip circumference [ Time Frame: 12, 24 weeks ]Anthropometric measures will be determined at the initial and follow-up visits (12,24 weeks).
- Plasma levels of Adiponectin [ Time Frame: initial visit, 12, 24 weeks ]Blood samples will be taken at the initial and follow-up visits (12,24 weeks) to determine adiponectin by Human Adiponectin/Acrp30 Quantikine ELISA (R&D Systems, USA)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01168700
|Contact: Patricio Lopez-Jaramillo, MD, PhD||577-6382828 ext email@example.com|
|Contact: Ronald G Garcia, MD, PhD||577-6399292 ext firstname.lastname@example.org|
|Medicine School, Universidad de Santander||Recruiting|
|Bucaramanga, Santander, Colombia, 0000000|
|Sub-Investigator: Yudy A Rodriguez, Bact|
|Sub-Investigator: Ronald G García, MD, PhD|
|Principal Investigator:||Patricio López-Jaramillo, MD, PhD||Universidad de Santander|